Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00242177 | Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability | PHASE1 | COMPLETED | 30 | — | — | Oct 1, 2003 | Oct 1, 2005 | Jul 22, 2019 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| ACTOS (Pioglitazone) | DRUG | - |
Inclusion Criteria: Informed consent must be signed and dated Clinically or laboratory definite RR MS Mild symptoms, with current EDSS between 1 and 6.5, and ambulatory Currently taking, and history (\>= 1 year) of taking Avonex or Rebif No relapses in past 3 months Historical annual relapse rate o...